145908-29-8

Basic information

• Product Name: 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER
• Synonyms: 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER;Methyl 2-(broMoMethyl)-4-chlorobenzoate;Benzoic acid, 2-(broMoMethyl)-4-chloro-, Methyl ester
• CAS NO: 145908-29-8
• Molecular Formula: C₉H₈BrClO₂
• Molecular Weight: 263.52
• Mol File: 145908-29-8.mol

Chemical Properties

• Boiling Point: 319.5°C at 760 mmHg
• Flash Point: 147°C
• Appearance: /
• Density: 1.561g/cm³
• Vapor Pressure: 0.000337mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER(145908-29-8)
• EPA Substance Registry System: 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER(145908-29-8)

Safety Data

• RIDADR: 3261
• HazardClass: 8
• PackingGroup: Ⅱ
• Hazardous Substances Data: 145908-29-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER is used as a chemical intermediate for the synthesis of pharmaceuticals, facilitating the creation of new drugs and enhancing the efficacy of existing medications. Its unique structure allows for versatile chemical reactions, making it a valuable component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER is utilized as an intermediate in the production of agrochemicals, including pesticides and herbicides. Its involvement in these processes helps to improve crop protection and increase agricultural yields.
Safety Precautions:
Given its potential to cause skin irritation and serious eye damage, 2-BROMOMETHYL-4-CHLORO-BENZOIC ACID METHYL ESTER requires careful handling and adherence to safety protocols. Proper protective equipment, such as gloves and safety goggles, should be worn when working with this compound to minimize the risk of exposure and associated health hazards.

InChI:InChI=1/C9H8BrClO2/c1-13-9(12)8-3-2-7(11)4-6(8)5-10/h2-4H,5H2,1H3

Upstream product

• 99585-12-3 4-chloro-2-methylbenzoic acid methyl ester 
• 7499-07-2 4-chloro-2-methylbenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 515133-98-9 C₁₅H₁₃ClO₃ 
• 1022984-23-1 5-chloro-2-(4-dimethylaminophenyl)-2,3-dihydroisoindol-1-one 
• 1192348-24-5 methyl 2-[(3-carbamoyl-5-chloro-2-iminopyridin-1(2H)-yl)methyl]-4-chlorobenzoate hydrobromide 
• 1001336-16-8 methyl 4-chloro-2-formylbenzoate 

Relevant articles and documents

Br?nsted Acid Catalyzed Dearomatization by Intramolecular Hydroalkoxylation/Claisen Rearrangement: Diastereo- and Enantioselective Synthesis of Spirolactams

Described herein is a novel Br?nsted acid catalyzed intramolecular hydroalkoxylation/Claisen rearrangement, allowing the practical and atom-economic synthesis of a range of valuable spirolactams from readily available ynamides in generally good to excellent yields with excellent diastereoselectivities and broad substrate scope. Importantly, an unexpected dearomatization of nonactivated arenes and heteroaromatic compounds is involved in this tandem sequence. Moreover, an asymmetric version of this tandem cyclization was also achieved by efficient kinetic resolution by chiral phosphoric acid catalysis. In addition, the [3,3]-rearrangement is shown to be kinetically preferred over the related [1,3]-rearrangement by theoretical calculations.

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

Rapid generation of novel benzoic acid–based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study

A series of novel xanthine derivatives 2a-l incorporating benzoic acid moieties were rapidly generated by using strategy of scaffold-hopping from our previously reported scaffold uracil to xanthine, a scaffold of approved drug linagliptin. After systematic structure-activity relationship (SAR) study around benzoic acid moieties, 5 novel DPP-4 inhibitors with low picomolar potency range (IC50 50 value of 0.1 nM for DPP-4, showed 22-fold improvement in inhibitory activity compared to lead compound uracil 1, its activity was 45-fold more potent than alogliptin. 2e, 2f, 2i and 2k were selected for pharmacokinetic evaluation, and 2f and 2i showed the better pharmacokinetic profiles after iv administration, but poor oral bioavailability. To improve the oral pharmacokinetic profile, prodrug design approach was performed around 2f and 2i. Esters of 2f and 2i were synthesized and evaluated for stability, toxicity and pharmacokinetics. Compound 3e, the methyl ester of compound 2f, was identified to demonstrate good stability, low toxicity and improved oral bioavailability, with 3-fold higher blood concentration compared to 2f in rats. The following in vivo evaluations revealed 3e provided a sustained pharmacodynamics effect for 48h, and robustly improved glucose tolerance in normal ICR and db/db mice in dose-dependent manner. Chronic treatments investigations demonstrated that 3e achieved more beneficial effects on fasting blood glucose levels and glucose tolerance than alogliptin in type 2 diabetic db/db mice. The overall results have shown that compound 3e has the potential to efficacious, safety and long-acting treatment for T2DM.

AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.

Iminopyridine Derivatives and Use Thereof

The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The pr

Isoindol-1,3-dione and isoindol-1-one derivatives with high binding affinity to β-amyloid fibrils

Based on the structural features of Indoprofen and PIB, a series of isoindol-1,3-diones 1a-k and isoindol-1-ones 2a-l were designed and synthesized. These 23 compounds were evaluated by competitive binding assay against aggregated Aβ42 fibrils using [125I]TZDM. All the isoindolone derivatives showed very good binding affinities with Ki values in the subnanomolar range (0.42-0.94 nM). Among them, isoindol-1,3-diones 1i and 1k and isoindol-1-ones 2c and 2i exhibited excellent binding affinities (Ki = 0.42-0.44 and 0.46-0.49 nM) than those of Indoprofen (Ki = 0.52 nM) and PIB (Ki = 0.70 nM). These results suggest that isoindolones could be served as a scaffold for potential AD diagnostic probes to monitor Aβ fibrils.

Doxepin analogs and methods of use thereof

The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

METHODS OF TREATING SLEEP DISORDERS

The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.